DDInter856 DDInter1297
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer. Niraparib was approved by the European Commission on November 16, 2017 and by Health Canada on June 27, 2019.
Niraparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Niraparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dasatinib
Niraparib {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Niraparib {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib
Niraparib may lead to a major life threatening interaction when taken with Natalizumab
Niraparib may lead to a major life threatening interaction when taken with Baricitinib